In theory, Nike should be killing it, as demand for athletic sneakers has been strong. But the apparel maker’s stock is down by a double-digit percentage year to date.
The DNA collection is not open to the public and is largely reserved for researchers and designers.
These stocks are all down more than 15% this year.